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Introduction: Increasing evidence has suggested that linear epitopes of antineutrophil cytoplasmic antibody (ANCA)
directed to myeloperoxidase (MPO) might provide clues to the pathogenesis of propylthiouracil (PTU)-induced
ANCA-associated vasculitis (AAV). This study mapped epitopes of MPO-ANCA in sera from patients with PTU-induced
MPO-ANCA (with or without vasculitis) and primary AAV, aiming to analyze certain epitopes associated with the
development of PTU-induced AAV.
Methods: Six recombinant linear fragments, covering the whole amino acid sequence of a single chain of MPO, were
produced from Escherichia coli. Sera from 17 patients with PTU-induced AAV, 17 patients with PTU-induced MPO-ANCA
but without clinical evidence of vasculitis, and 64 patients with primary AAV were collected at presentation. Of the 17
patients with PTU-induced AAV, 12 also had sera at remission. The epitope specificities were detected by
enzyme-linked immunosorbent assay by using the recombinant fragments as solid-phase ligands.
Results: Compared with patients with PTU-induced MPO-ANCA but without clinical vasculitis, sera from PTU-induced
AAV patients showed significantly higher reactivity against the H1 fragment of MPO (optical density values: 0.17 (0.10 to
0.35) versus 0.10 (0.04 to 0.21), P = 0.038) and could recognize a significantly higher number of fragments (two (none to
four) versus one (none to two), P = 0.026). Compared with sera from primary AAV patients, sera from PTU-induced AAV
patients had significantly higher reactivity to the P fragment and the H4 fragment (47.1% versus 14.1% P < 0.001; 41.2%
versus 14.1%, P = 0.034, respectively), and could recognize a significantly higher number of fragments (two (none to
four) versus one (none to two), P = 0.013]. Among the 12 PTU-induced AAV patients with sequential samples, the
number of fragments recognized in remission was significantly less than that in initial onset (two (none to four) versus
none (none to 0.75), P < 0.001].
Conclusions: Linear epitopes of MPO molecules might be associated closely with PTU-induced AAV. In particular, the P
and H4 fragments may be important epitopes in PTU-induced AAV.Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) includes granulomatosis with polyangiitis
(GPA), microscopic polyangiitis (MPA), and eosinophilic
granulomatosis with polyangiitis (EGPA). ANCAs are
serologic hallmarks for the previously mentioned primary* Correspondence: leimeng@public3.bta.net.cn
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reproduction in any medium, provided the orsmall-vessel vasculitis. Proteinase 3 (PR3) and myeloper-
oxidase (MPO) are the two most important target antigens
of ANCA [1,2]. ANCAs are also involved in the pathogen-
esis of AAV [3-5]. One of the most important develop-
ments in the ANCA field is the increasing recognition of a
number of drugs that could induce AAV. Among these
drugs, the most often implicated one is propylthiouracil
(PTU) [6,7], a common antithyroid agent. It was reported
that most patients with PTU-induced AAV are MPO-
ANCA positive [8]. The immunologic characteristics oftd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epitopes, are contributors to PTU-induced AAV [9-13].
Many similarities in clinical manifestations are present
between PTU-induced AAV and primary AAV. However,
it has been suggested that the mechanism involved in the
synthesis of PTU-induced MPO-ANCA might be different
from that in patients with primary AAV [12]. For example,
our previous study preliminarily suggested that epitopes
recognized by PTU-induced MPO-ANCA were different
from those recognized by MPO-ANCA from patients with
primary AAV [12]. By investigating the association be-
tween epitope profiles and clinical manifestations of PTU-
induced AAV in children, Fujieda et al. [13] speculated
that the clonality of MPO-ANCA might be a risk factor
for developing vasculitis. These findings implied that epi-
tope mapping of MPO, especially linear epitopes, might
draw some distinction between PTU-induced AAV and
primary AAV, and provide some clues for exploring the
pathogenesis of PTU-induced AAV.
In patients with PTU-induced AAV, after discontinu-
ation of the offending drug and initiation of immuno-
suppressive treatment, patients often achieve remission
quickly, with ANCA avidity and titers declining [11]. In-
vestigating epitopes of MPO in sequential serum samples
(that is, in active stage and remission of PTU-induced
AAV) may help us to find the epitope(s) associated with
active diseases.
Moreover, in our previous cross-sectional study, it was
found that among patients with PTU-induced ANCA,
only about one in five developed clinically evident vascu-
litis [14]; even in those who were MPO-ANCA positive,
not all developed clinically evident vasculitis [15]. It is rea-
sonable to investigate whether the difference of epitope(s)
of MPO contribute to the development of these two differ-
ent phenotypes (that is, with or without vasculitis).
With these previously mentioned questions in mind,
we produced six linear recombinant deletion mutants of
the MPO molecule and mapped the epitopes of MPO-
ANCA in sera from both patients with PTU-induced




Seventeen patients with PTU-induced AAV, diagnosed
at Peking University First Hospital from October 1999
to October 2005, were recruited in this study. All the pa-
tients met the criteria of the Chapel Hill Consensus
Conference definition of AAV [16]. PTU-induced AAV
was defined as follows: (a) the signs and symptoms of
vasculitis were temporally related to using PTU, and
regressed with its discontinuation; (b) serum ANCA was
positive, especially in those with multi-antigenicity; and
(c) medical conditions that mimicked vasculitis wereexcluded, especially infections and malignancies, and
other definable types of vasculitis [17]. At the time of
diagnosis, all the patients were positive for MPO-ANCA.
Serum samples were collected from the 17 patients on
diagnosis before the initiation of immunosuppressive
treatments. Serum samples from 12 of these 17 patients
who achieved remission were collected at their regular
ambulatory visits. Serum MPO-ANCA in all these 12
patients remained positive despite clinical remission. Re-
mission was defined as “absence of disease activity at-
tributable to active disease qualified by the need for
ongoing stable maintenance immunosuppressive ther-
apy”, as described previously [18]. Serum samples were
also collected from the following participants: (a) 17 pa-
tients with PTU-induced serum MPO-ANCA but with-
out clinical evidence of vasculitis; (b) 64 patients with
primary AAV that were MPO-ANCA positive; (c) three
patients with PTU-induced lupus. PTU-induced lupus
was defined as previously described [19]; and (d) 35
healthy blood donors were collected as normal controls.
Sera from all subjects were obtained and kept at −70°C
until use.
The research was in compliance of the Declaration of
Helsinki and approved by the ethics committee of
Peking University First Hospital. Written informed con-
sent was obtained from each participant.Detection of MPO-ANCA
All sera were screened for ANCA with indirect im-
munofluorescence by using precooled ethanol-fixed
normal peripheral neutrophils as substrate, according to
the manufacturer (Euroimmun, Lübeck, Germany), and
MPO-ANCAs were measured with enzyme-linked im-
munosorbent assay (ELISA), as described previously [20].Preparation of recombinant MPO fragments
Six recombinant linear fragments, covering the whole-
length amino acid sequence of a single chain of MPO (that
is, P, L, H1, H2, H3, and H4) were prepared as deletion
mutants of MPO from Escherichia coli, as described in our
previous study [21]. The amino acid sequences of the six
fragments were as follows: 49 to 164 for propeptide (P),
165 to 272 for light chain (L), 279 to 409 for the N terminal
of the heavy chain (H1), 399 to 519 for the second part of
the heavy chain (H2); similarly, 510 to 631 for H3 and 622
to 745 for H4. All the six recombinant MPO fragments
were highly purified as proteins tagged with histidines with
>80% purity by Ni-NTA column chromatography (an add-
itional figure shows this in more detail (see Additional
file 1)). The mature MPO, which is produced by two heavy-
light protomer units interacting, is a symmetric homodi-
mer of approximately 150 kDa, with each half linked by a
disulfide bond between C319 residues of the heavy subunit
Table 1 Clinical data of 17 patients with PTU-induced
AAV and 64 patients with primary AAV
PTU-induced AAV Primary AAV
(n = 17) (n = 64)
Male/female 2/15 32/32
Age (years) 30.8 ± 15.2 60.48 ± 15.14
Scr (μM)
Mean ± SD 75.62 ± 40.64 339.11 ± 237.71
Range 38-176.9 70-1007
Renal insufficiency at diagnosis 13 (76.4%) 48 (75%)
ESR (mm/1 hour) 46.92 ± 38.86 70.05 ± 40.14
Skin rash 5(29.4%) 7 (10.9%)
Arthralgia 9(52.9%) 15(23.4%)
Muscle pain 6 (35.3%) 10 (15.6%)
Lung 6 (35.3%) 43 (67.2%)
ENT 6 (35.2%) 27(42.2%)
Ophthalmic 2 (11.8%) 14(21.9%)
Gastrointestinal 3(17.6%) 11(17.2%)
Nervous system 1 (5.9%) 10(15.6%)
BVAS
Mean ± SD 17.1 ± 5.5 20.27 ± 5.18
Range 7-31 13-36
AAV ANCA-associated vasculitis, BVAS Birmingham Vasculitis Activity Scores,
ENT ear, nose, and throat, SD standard deviation.
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Determination of the reactivity of recombinant fragment
of MPO by ELISA
Highly purified recombinant MPO fragment were recon-
stituted to 10 μg/ml with coating buffer (0.05M bicar-
bonate buffer, pH 9.6). A 100-μl portion of the mixture
was then plated to a well of a polystyrene microtiter
plate (Nunc Immunoplate; Nunc, Roskilde, Denmark)
and kept overnight at 4°C. Every plate contained native
MPO (2 μg/well) as a positive antigen control. The plate
was washed 3 times with PBS containing 0.1% Tween-20
(PBST) (Chemical Reagents, Beijing, China). Then 2%
BSA diluted by PBS was used to block the nonspecific
binding sites. The sera of subjects were diluted to 1:100
by PBST/0.5M NaCl (NaCl 0.5M, KCl 2.7 mM,
Na2HPO4 10 mM, KH2PO4 2 mM, pH 7.4), and were
added in duplication. Every plate contained positive,
negative, and blank controls. The plate was incubated at
37°C for 1 hour and then washed 3 times with PBST, and
the binding was detected with alkaline phosphatase-
conjugated goat anti-human IgG (Fc specific; Sigma, St.
Louis, MO, USA) at a dilution of 1:5,000. The plate was
washed 3 times with washing buffer and the P-nitrophenyl
phosphate (pNPP, 1 mg/ml; Sigma) was used in substrate
buffer [1M diethanolamine and 0.5 mM MgCl2 (pH 9.8)].
The results were recorded as the absorbance at 405 nm (A
405 nm), and samples were considered positive if the A
405 nm exceeded mean + 2 SD of the A 405 nm of the
sera from 35 normal blood donors.
Detection of anti-endothelial cell antibodies and
autoantibodies directed to specific ANCA antigens other
than MPO
AECA as well as ANCA directed to six specific target
antigens, including proteinase 3, cathepsin G, lactoferrin,
human leukocyte elastase (HLE), azurocidin, and bac-
tericidal/permeability-increasing protein (BPI) were ex-
amined. AECA was detected by Western blot analysis,
and ANCA directed to the previously mentioned six
specific target antigens were detected with ELISA, as de-
scribed in our previous study [22,23].
Statistical analysis
Differences of quantitative parameters between groups
were assessed by using the t test (for data that were nor-
mally distributed) or nonparametric test (for data that
were not normally distributed). Differences in qualitative
data were compared by using χ2 tests. The difference
was considered significant if a P value was <0.05. Ana-
lysis was performed with SPSS statistical software pack-
age (version 18.0, Chicago, IL, USA).Results
General data of the patients
Among the 17 PTU-induced AAV patients, 15 were fe-
male and two were male patients, with an age of 30.8 ±
15.2 (range, 11–58) years at diagnosis. The Birmingham
Vasculitis Activity Scores (BVASs) were 17.1 ± 5.5 (range,
7 to 31 years). The level of initial serum creatinine was
75.62 ± 40.64 μM. Among the 64 primary AAV patients,
32 were male and 32 were female patients, with an age
of 60.5 ± 15.1 (range, 15 to 83) years at diagnosis. The
BVASs were 20.27 ± 5.18 years (range, 13 to 36 years)
(Table 1).
Among the 12 PTU-induced AAV patients at remis-
sion, 10 were female and two were male patients, with
an age of 34.7 ± 20.0 (range, 11 to 76) years at diagnosis.
The BVAS levels were all zero (Table 2).
Among the patients with PTU-induced MPO-ANCA,
except for only one with clinical vasculitis had positive
ANA, all the patients with and without clinical vasculitis
were negative for ANA, anti-dsDNA, anti-histone, and
anti-Sm antibodies.
Among the three patients with PTU-induced lupus, all
were women, with age of 17, 30 and 57 years at diagno-
sis, respectively. All these three patients were positive
serum ANA.
Table 2 Cutoff values in the assay of autoantibodies
against various linear fragments of MPO
Epitope Mean SD Cutoff values
Pre 0.058 0.033 0.124
H1 0.076 0.066 0.208
H2 0.074 0.049 0.172
H3 0.061 0.040 0.141
H4 0.094 0.070 0.234
L 0.051 0.043 0.137
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of MPO
The cutoff values, which were set as the mean + 2 SD of
A405 nm of the sera from 35 normal blood donors, in the
assay of autoantibodies against various linear fragments of
MPO were listed in Table 2. Serum samples from these 17
PTU-induced AAV patients in active stage, 12 PTU-
induced AAV patients in remission, and 17 PTU-induced
MPO-ANCA-positive patients but without clinical evi-
dence of vasculitis were demonstrated to recognize all the
six constructed linear protein fragments. Sera from 15
(88.2%) of 17 patients with PTU-induced AAV and 11
(61.1%) of 18 patients with positive PTU-induced MPO-
ANCA but without clinical vasculitis could recognize at
least one peptide. Meanwhile, among the 64 primary AAV
patients, 37 (57.8%) of 64 patients showed a positive reac-
tion to one or more linear fragments of the MPO chain.
The reactivity distributed throughout the MPO molecule
(Figure 1). None of sera from patients with PTU-induced
lupus could recognize the recombinant fragments of
MPO, except that only one could recognize L chain. In
the patients with PTU-induced AAV, no significant associ-
ation was found between levels of antibodies againstFigure 1 The frequencies of sera binding to different protein
fragments of MPO in patients with PTU-induced AAV, patients
with primary AAV, and patients with PTU-induced MPO-ANCA
but without clinical vasculitis.various epitopes of MPO and clinical parameters, includ-
ing serum creatinine, ESR, C-reactive protein, numbers
with organ involvement and BVAS.Differences of epitopes between patients with PTU-induced
MPO-ANCA with and without clinical vasculitis
We compared the MPO epitopes between the 17 pa-
tients with PTU-induced AAV and the 17 patients with
PTU-induced MPO-ANCA but without clinical vascu-
litis. Compared with sera from patients with PTU-
induced MPO-ANCA but without clinical vasculitis, sera
from PTU-induced AAV patients showed significantly
higher reactivity against the H1 fragment of MPO [OD
values: 0.17(0.10 to 0.35) versus 0.10(0.04 to 0.21),
P = 0.038] (Figure 2). The number of fragments recog-
nized in PTU-induced AAV was significantly more than
that in PTU-induced MPO-ANCA but without clinical
vasculitis (2(0 to 4) versus 1(0 to 2), P = 0.026).Differences of epitopes between patients with PTU-induced
AAV and with primary AAV
We compared the MPO epitopes between the 17 pa-
tients with PTU-induced AAV and the 64 patients with
primary AAV. Compared with that from primary AAV
patients, significantly higher proportions of sera from
PTU-induced AAV patients had reactivity to P fragment
and H4 fragment. (47.1% versus 14.1%; P < 0.001; 41.2%
versus 14.1%; P = 0.034, respectively). The number of
fragments recognized in sera from patients with PTU-
induced AAV was significantly more than that in sera
from patients with primary AAV (2(0 to 4) versus. 1(0 to 2);
P = 0.013].Figure 2 The OD values of sera binding to different protein
fragments of MPO in patients with PTU-induced AAV and in
patients with PTU-induced MPO-ANCA but without
clinical vasculitis.
Table 4 The prevalence of AECA and autoantibodies

















(n = 17) (n = 11)
AECA 15 (88.2%) 0 (0) <0.001
PR3 5 (29.4%) 1 (9.1%) 0.380
HLE 12 (70.6%) 3 (27.3%) 0.011
Lactoferrin 14 (82.4%) 5 (45.5%) 0.010
Cathepsin G 11 (64.7%) 0 (0) <0.001
BPI 0 (0) 1 (9.1%) 0.209




3 (2–4) 0 (0–2%) <0.001
PR3, Proteinase 3; HLE, human leukocyte elastase; BPI,
bactericidal/permeability-increasing protein.
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AAV in active stage and in remission
Among the 12 PTU-induced AAV patients with sequen-
tial samples (that is, in active stage and in remission),
the number of fragments recognized in remission was
significantly less than that in initial onset (2(0 to 4) ver-
sus 0(0 to 0.75); P < 0.001). Nine of the 12 patients at re-
mission (patients 1, 2, 4, 5, 6, 7, 8, 9, and 11 in Table 3)
recognized none of the six fragments, while the other 3
(patient No. 3, 10 and 12 in Table 3) recognized one or
three fragments, respectively. The binding to linear frag-
ments in remission was limited to the P, H1, H2, and H4
fragments. Among the four patients (patients 3, 5, 10,
and 12 in Table 3) who had antibodies to H4 in the ac-
tive stage, antibodies to H4 turned negative in two pa-
tients (patients 5 and 12 in Table 3) in remission; among
the other eight patients who were seronegative for H4
during the active stage, none developed reactivity to H4
in remission.
The prevalence of AECA and autoantibodies directed to
specific ANCA antigens other than MPO
Fifteen of 17 patients with PTU-induced vasculitis were
serum AECA positive, whereas none of the patients with
PTU-induced MPO-ANCA but without clinical vasculitis
was AECA positive (88.2% versus None; P < 0.001). Mean-
while, the prevalences of antibodies against the proteinase
3, cathepsin G, lactoferrin, HLE, and azurocidin were sig-
nificantly higher in patients with PTU-induced vasculitis
than those in patients with PTU-induced MPO-ANCA
but without clinical vasculitis (Table 4). No significant cor-
relation was found between the previously mentioned
autoantibodies (that is, AECA and autoantibodies directedTable 3 The reactivity of MPO-ANCA against the linear
peptides of MPO of the 12 PTU-induced AAV patients

















-, negative for any fragment test.to specific ANCA antigens other than MPO, and anti-
bodies against various linear fragments of MPO.
Discussion
Cumulative evidence has proved the pathogenic role of
ANCA, in particular, MPO-ANCA, in the development
of AAV. ANCA can mediate the activation of primed
neutrophils, resulting in a respiratory burst and degranu-
lation, which could play a direct pathogenic role in vas-
culitic lesions [3,24]. Xiao et al. [4] found that transfer
of anti-MPO IgG from MPO-deficient mice immunized
with mouse MPO into wild-type mice led to pauci-
immune vasculitis. Our previous studies found that in
PTU-induced AAV, the most important target antigen of
ANCA is MPO [14], and the immunologic characteris-
tics of MPO-ANCA are associated with the development
of PTU-induced ANCA-associated vasculitis [25,26].
MPO epitopes recognized by human sera were both
conformational and linear epitopes [27,28]. The current
study investigated linear epitopes of MPO in patients with
PTU-induced ANCA-associated vasculitis. Our previous
study found that among patients with PTU-induced
ANCA, the prevalence of serum MPO-ANCA was signifi-
cantly higher in patients with clinical vasculitis than that
in patients without clinical vasculitis [23]. Consistently,
the current study found that sera from patients with PTU-
induced AAV recognized significantly more fragments
compared with sera from PTU-induced MPO-ANCA
without clinical vasculitis. Furthermore, among the 12
PTU-induced AAV patients with sequential samples, the
number of recognized epitopes declined rapidly once
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ANCA were persistently positive from active stage to re-
mission. All these findings suggest that the linear epitopes,
compared with conformational ones, might be associated
more closely with PTU-induced AAV.
Compared with sera from primary AAV patients, sera
from PTU-induced AAV patients could recognize signifi-
cantly higher numbers of fragments, and had significantly
higher reactivity to P fragment and H4 fragment. More-
over, among the four patients who had antibodies to H4 in
the active stage, antibodies to H4 turned negative in two
patients in remission; among the other eight patients who
were seronegative for H4 during the active stage, no one
developed reactivity to H4 in remission. These findings in-
dicate that the linear epitope might be of more closely as-
sociated with PTU-induced AAV than that in primary
AAV patients. However, the detailed role of antibody di-
rected to the P and H4 fragment in the development of
PTU-induced vasculitis demands further investigation.
We also found that PTU-induced AAV patients had
higher reactivity against the H1 fragment compared with
patients with PTU-induced MPO-ANCA but without
clinical vasculitis. However, one patient with PTU-induced
AAV was negative for H1 during the active stage but de-
veloped reactivity to H1 in remission. Therefore, the sig-
nificance of the H1 fragment in PTU-induced AAV
remains more uncertain.
Some limitations existed in our study. First, patients
with PTU-induced AAV and patients with primary AAV
were not age- or gender-matched because of the charac-
teristics of these two diseases per se. Second, the sample
size was relatively limited because PTU-induced AAV is
an uncommon disease.Conclusions
The current study provided evidence that PTU-induced
MPO-ANCA could recognize linear epitopes throughout
the corresponding antigen molecule MPO. Linear epi-
topes of the MPO molecule, compared with conform-
ational ones, might be associated more closely with
PTU-induced AAV. In particular, the P and H4 frag-
ments may be important epitopes in PTU-induced AAV.Additional files
Additional file 1: Figure S1. Schema of linear epitopes of MPO-ANCA.
Description: Six recombinant linear fragments, P, L, H1, H2, H3, and H4, were
produced by using Escherichia coli. P represents propeptide part, amino acids
(aa) 49 to 164; L represents light chain, aa165 to 272; H1 to H4 represent four
fragments of the heavy chain, H1 for aa279 to 409, H2 for aa399 to 519, H3
for aa510 to 631, and H4 for 622 to 745. About 10 amino acids overlapped
between the two adjacent fragments on the heavy chain.
Additional file 2: Figure S2. Structure of mature MPO. Description: The
mature MPO is produced by two heavy-light protomer units interacting,which then formed a symmetric homodimer of approximately 150 kDa,
with each half linked by a disulfide bond (MMDB ID 48480).
Additional file 3: Figure S3. Location of L, H1, H2, H3, and H4
fragments on MPO. Description: L, H1, H2, H3, and H4 fragments were
marked in different colors in one heavy-light protomer unit (MMDB ID
75307) as follows: L by purple; H1, H2, H3, and H4 by yellow. The second
row was viewed from the opposite side of the first row.
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